Research: Mechanisms of Pulmonary Hypertension associated with Chronic Lung Diseases. Chronic lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF) are currently the 3rd largest killers in the US. An important and deadly complication of COPD and IPF is the development of Pulmonary Hypertension (PH). PH is a deadly disorder that is characterized by remodeling of the vasculature, increased blood pressure in the pulmonary circulation (>25mmHg) that results in right-sided heart attack and death. Currently, there are no treatments available for this disorder, in part due to our lack of understanding of the pathogenesis of PH in patients with chronic lung disease. Our research has identified the adenosine A2B receptor, a receptor that is elevated following conditions of cell injury and stress, and hyaluronan, a component of the lung extracellular matrix, as potential targets for the treatment of PH in chronic lung disease. Our research efforts are focused on uncovering the mechanisms of adenosine signaling and hyaluronan that lead to PH in chronic lung disease.
Fun Facts: I previously trained in Montreal, Quebec at McGill University from 2006 to 2010 where I completed my first postdoc on airway smooth muscle remodeling in asthma. Prior to that I lived in Basel, Switzerland, where I pursued my PhD on “Experimental Pulmonary Diseases assessed by Magnetic Resonance Imaging”, a joint venture with Novartis and King’s College London (UK) where I graduated in 2006. Having spent a lot of time in cold countries, I was happy to move to Houston in May 2010 where I started as a postdoc and was promoted to Research Assistant Professor in September 2012. Other than lung diseases, I am interested in ocean life; I have a saltwater aquarium at home and I am a certified scuba diver! Originally from Barcelona, I may be hard to find if FC Barcelona is playing a champions league game or against Real Madrid!
UTHealth Medical School
Department of Biochemistry and Molecular Biology
6431 Fannin Street, MSB 6.214
Houston, Texas 77030
713-500-5331 Direct 713-500-0652 Fax
Lab: MSB 6.310; 713-500-6034
Ph.D. - King's College London
Postdoctoral Fellow - McGill University, Canada
Mechanisms of pulmonary hypertension (PH) associated with chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF); Mechanisms of adenosine signaling and hyaluronan that lead to PH in chronic lung diseases.
Karmouty-Quintana H, Weng T, Garcia-Morales LJ, Chen NY, Pedroza M, Zhong H, Molina JG, Bunge R, Bruckner BA, Xia Y, Johnston RA, Loebe M, Zeng D, Seethamraju H, Belardinelli L, Blackburn MR.
Am J Respir Cell Mol Biol. 2013 Dec;49(6):1038-47.read more
Karmouty-Quintana H, Xia Y, Blackburn MR.
J Mol Med (Berl) 91(2):173-81, 2013.
PMCID: PMC3606047read more
Karmouty-Quintana H, Zhong H, Acero L, Weng T, Melicoff E, West JD, Hemnes A, Grenz A, Eltzschig HK, Blackwell TS, Xia Y, Johnston RA, Zeng D, Belardinelli L, Blackburn MR.
FASEB J 26(6):2546-57, 2012
Karmouty-Quintana H, Siddiqui S, Hassan M, Tsuchiya K, Risse PA, Xicota-Vila L, Marti-Solano M, Martin JG.
Am J Physiol Lung Cell Mol Physiol 302(8):L736-45, 2012.
PMID: 22287614read more
Karmouty-Quintana H, Tamimi F, McGovern TK, Grover LM, Martin JG, Barralet JE.
Biomaterials 31(23):6050-9, 2010.
Karmouty-Quintana H, Blé FX, Cannet C, Zurbruegg S, Fozard JR, Page CP, Beckmann N.
Br J Pharmacol 154(5):1063-72, 2008.
PMCID: PMC2451044read more
Karmouty-Quintana H, Cannet C, Zurbruegg S, Blé FX, Fozard JR, Page CP, Beckmann N.
J Magn Reson Imaging 26(4):941-9, 2007
Karmouty-Quintana H, Cannet C, Sugar R, Fozard JR, Page CP, Beckmann N.
Br J Pharmacol 150(8):1022-30, 2007
PMCID: PMC2013907read more
Karmouty Quintana H, Mazzoni L, Fozard JR.
Auton Autacoid Pharmacol 25(4):167-70, 2005.